Siebenhüner AR, et al. - This prospective, non-randomized phase II study was planned to determine the feasibility and efficacy of cisplatin and gemcitabine as adjuvant treatment in patients with resected Biliary tract cancer (BTC). Observations revealed that in these patients, treatment with gemcitabine either alone or combined with cisplatin was feasible and well tolerated.